11月21日，纳微科技跌5.92%，成交额1.57亿元。两融数据显示，当日纳微科技获融资买入额1978.28万 元，融资偿还2699.56万元，融资净买入-721.28万元。截至11月21日，纳微科技融资融券余额合计3.85 亿元。 机构持仓方面，截止2025年9月30日，纳微科技十大流通股东中，中欧医疗健康混合A（003095）位居 第十大流通股东，持股692.69万股，相比上期减少126.18万股。 融资方面，纳微科技当日融资买入1978.28万元。当前融资余额3.83亿元，占流通市值的3.55%，融资余 额超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 融券方面，纳微科技11月21日融券偿还1900.00股，融券卖出2000.00股，按当日收盘价计算，卖出金额 5.34万元；融券余量5.59万股，融券余额149.25万元，超过近一年90%分位水平，处于高位。 资料显示，苏州纳微科技股份有限公司位于江苏省苏州工业园区百川街2号，成立日期2007年10月22 日，上市日期2021年6月23日，公司主营业务涉及高性能纳米微球材料的研发、规模化生产、销售及应 用服务,为生物医药、平板显示、分析检测及体 ...

Group 1 - The core business of Nanwei Technology involves the research, large-scale production, sales, and application services of high-performance nano microsphere materials, serving clients in biomedicine, flat panel displays, analytical testing, and in vitro diagnostics [2] - As of September 30, 2025, Nanwei Technology achieved operating revenue of 671 million yuan, representing a year-on-year growth of 22.01%, and a net profit attributable to shareholders of 108 million yuan, with a significant year-on-year increase of 156.56% [2] - The company has distributed a total of 115 million yuan in dividends since its A-share listing, with 86.84 million yuan distributed over the past three years [3] Group 2 - On November 14, Nanwei Technology's stock price fell by 1.02%, with a trading volume of 142 million yuan [1] - The financing buy-in amount for Nanwei Technology on November 14 was 22.54 million yuan, while the financing repayment was 21.62 million yuan, resulting in a net financing buy-in of 918,600 yuan [1] - The total balance of margin trading for Nanwei Technology as of November 14 was 363 million yuan, with the financing balance accounting for 2.98% of the circulating market value, indicating a high level compared to the past year [1]

Core Insights - Nanwei Technology reported a revenue of 671 million yuan for the first three quarters of 2025, representing a year-on-year growth of 22.01% [1] - The net profit attributable to shareholders reached 108 million yuan, showing a significant increase of 156.56% year-on-year [1] - The company’s basic earnings per share stood at 0.27 yuan [1] Financial Performance - The gross profit margin for the first three quarters of 2025 was 72.16%, up by 1.10 percentage points year-on-year, while the net profit margin was 16.75%, an increase of 9.24 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin was 72.32%, reflecting a year-on-year increase of 3.45 percentage points and a quarter-on-quarter increase of 0.85 percentage points [2] - The net profit margin for Q3 2025 was 18.18%, up 19.32% year-on-year and 1.61 percentage points quarter-on-quarter [2] Expense Analysis - Total operating expenses for Q3 2025 amounted to 358 million yuan, an increase of 38.49 million yuan year-on-year [2] - The expense ratio was 53.41%, a decrease of 4.75 percentage points compared to the same period last year [2] - Sales expenses increased by 2.83%, management expenses rose by 26.39%, and R&D expenses grew by 14.20%, while financial expenses decreased by 102.90% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 16,100, an increase of 992 from the end of the previous half-year, representing a growth of 6.57% [2] - The average market value per shareholder increased from 610,500 yuan at the end of the previous half-year to 724,600 yuan, a rise of 18.70% [2] Company Overview - Nanwei Technology, established on October 22, 2007, is located in Suzhou Industrial Park, Jiangsu Province, and was listed on June 23, 2021 [3] - The company specializes in the research, large-scale production, sales, and application services of high-performance nano-microsphere materials, serving clients in biomedicine, flat panel displays, analytical testing, and in vitro diagnostics [3] - The main business revenue composition includes chromatography fillers and media products (57.62%), chromatography analysis instruments and accessories (19.72%), and other related products and services [3]

Core Viewpoint - Nanwei Technology experienced a decline of 2.94% in stock price on October 9, with a trading volume of 199 million yuan, indicating a potential shift in investor sentiment [1] Financing Summary - On October 9, Nanwei Technology had a financing buy-in amount of 23.78 million yuan and a financing repayment of 29.94 million yuan, resulting in a net financing outflow of 6.16 million yuan [1] - The total financing and securities balance for Nanwei Technology reached 351 million yuan, with the financing balance accounting for 3.09% of the circulating market value, indicating a high level compared to the past year [1] - The company had a financing buy-in of 23.78 million yuan on the same day, with a financing balance of 350 million yuan, which is above the 80th percentile of the past year [1] Securities Lending Summary - On October 9, Nanwei Technology repaid 4,287 shares in securities lending and sold 3,700 shares, with a selling amount of 103,700 yuan based on the closing price [1] - The remaining securities lending volume was 37,400 shares, with a balance of 1.05 million yuan, also exceeding the 80th percentile of the past year [1] Company Overview - Nanwei Technology, established on October 22, 2007, and listed on June 23, 2021, specializes in the research, production, and sales of high-performance nano-microsphere materials for various applications, including biomedicine and diagnostics [2] - The company's revenue composition includes 57.62% from chromatography fillers and media, 19.72% from chromatography instruments and accessories, and 10.44% from liquid chromatography columns and sample pretreatment products [2] - As of June 30, 2025, Nanwei Technology reported a revenue of 414 million yuan, a year-on-year increase of 21.74%, and a net profit attributable to shareholders of 63.31 million yuan, reflecting a growth of 40.52% [2] Dividend Summary - Since its A-share listing, Nanwei Technology has distributed a total of 115 million yuan in dividends, with 86.84 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Nanwei Technology was 15,100, an increase of 2.29% from the previous period, with an average of 26,739 circulating shares per person, a decrease of 2.24% [2][3]

Core Viewpoint - Nanwei Technology experienced a decline of 5.01% on September 23, with a stock price of 25.42 yuan per share and a total market capitalization of 10.265 billion yuan [1] Company Overview - Nanwei Technology, established on October 22, 2007, and listed on June 23, 2021, is located in Suzhou Industrial Park, Jiangsu Province. The company specializes in the research, large-scale production, sales, and application services of high-performance nano microsphere materials [1] - The main business revenue composition includes: 57.62% from chromatography fillers and chromatography media products, 19.72% from chromatography analysis instruments and accessories, 10.44% from liquid chromatography columns and sample pretreatment products, 5.02% from protein chromatography systems and accessories, 3.98% from microsphere products for optoelectronic fields, 1.35% from other products, 1.02% from separation and purification technology services, 0.78% from core microsphere products for IVD, and 0.06% from other supplementary products [1] Fund Holdings - According to data, one fund under Huatai PineBridge holds a significant position in Nanwei Technology. The Huatai PineBridge Science and Technology Innovation Board 2-Year Open Mixed Fund (506006) held 1.0052 million shares in the second quarter, accounting for 1.79% of the fund's net value, ranking as the tenth largest holding [2] - The fund has a current scale of 1.285 billion yuan and has achieved a return of 27.47% year-to-date, ranking 3368 out of 8172 in its category. Over the past year, it has returned 75.98%, ranking 1457 out of 7995, and since inception, it has returned 18.32% [2] Fund Manager Information - The fund manager of Huatai PineBridge Science and Technology Innovation Board 2-Year Open Mixed Fund (506006) is Xia Zheng'an, who has been in the position for 2 years and 343 days. The total asset scale of the fund is 1.418 billion yuan, with the best fund return during the tenure being 35.05% and the worst being 17.35% [3]